You are here: Industry Insights > AstraZeneca

News List

US widens use of AZ’ Tagrisso in lung cancer pharmatimes
April 23, 2018
AstraZeneca’s Tagrisso has been approved in the US as a first-line treatment for patients with metastatic non-small-cell lung cancer whose tumours have epidermal growth factor receptor (EGFR) mutations.
AstraZeneca’s Tagrisso Nabs Another Lung Cancer Approval biospace
April 20, 2018
FDA approved AstraZeneca’s Tagrisso (osimertinib) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) in tumors with epidermal growth factor receptor (EGFR) mutations.
FDA’s Chowdhury Leaves to Take Exec Position at AstraZeneca biospace
April 20, 2018
Badrul Chowdhury has left the agency as Senior Vice President of the Research Department at AstraZeneca and MedImmune Development.
Highmark Signs Outcomes-Based Agreement with AstraZeneca for Symbicort americanpharmaceuticalreview
April 19, 2018
Highmark has entered into an outcomes-based contract with AstraZeneca for Symbicort.
AstraZeneca strengthens innovation partnership in India expressbpd
April 19, 2018
AstraZeneca has announced an investment of $90 million in India over the next five years to develop local skills, build scientific innovation and promote quality manufacturing
AZ’s Tagrisso brings ‘unprecedented’ benefit in untreated NSCLC pharmaphorum
April 18, 2018
AstraZeneca says its lung cancer drug Tagrisso has produced “unprecedented” survival benefit from first-line use in some patients with advanced disease.
AZ’s Tagrisso brings ‘unprecedented’ benefit in untreated NSCLC pharmaphorum
April 17, 2018
AstraZeneca says its lung cancer drug Tagrisso has produced “unprecedented” survival benefit from first-line use in some patients with advanced disease.
Hanmi scraps development of lung cancer drug Olita in face of competition from AstraZeneca's Tagrisso firstwordpharma
April 16, 2018
Hanmi Pharmaceutical announced Friday that it will end development of the lung cancer therapy Olita (olmutinib) due to difficulties recruiting patients for pivotal studies and the cancellation of licensing deals for the third-generation tyrosine kinase in
Hanmi terminates lung cancer drug after being muscled out by AZ's Tagrisso pharmafile
April 16, 2018
South Korea’s Hanmi Pharmaceutical has announced its intention to terminate development of its lung cancer drug Olita (olmutinib) as it admits that circumstances within the space have meant that continued R&D costs would “eclipse its value”.
Owlstone adds AstraZeneca to roster of Breath Biopsy partners pharmaphorum
April 13, 2018
Owlstone Medical, one of the UK’s most promising medtech start-ups, is continuing its expansion into pharma partnering via a new deal with AstraZeneca.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page